Researchers have developed and validated a clinical scoring system that could help guide treatment decisions among patients with multiple myeloma.
Researchers conducted a validation study of four breast cancer risk models currently in use.
Researchers found that the HSD3B1 genotype may be a predictive biomarker for the use of certain prostate cancer therapies.
The DYNAMO study investigated the oral PI3K gamma inhibitor duvelisib in heavily pretreated indolent non-Hodgkin lymphoma patients.
The addition of denosumab to adjuvant aromatase inhibitor therapy offered improved outcomes in women with postmenopausal HR+ early breast cancer.
Researchers investigated the risk of subsequent primary neoplasms in survivors of adolescent and young adult cancer.
A score derived from CT imaging using a machine learning radiomics approach was able to reliably identify epithelial ovarian cancer patients with poor survival outcomes.
The latest trial results are based on a larger patient population and were reported at the 2019 ASCO Genitourinary Cancers Symposium.
The results of the double-blind, phase III trial were presented at the 2019 ASCO Genitourinary Cancers Symposium.
Researchers tested whether conservative management of adnexal masses classified as benign could lead to subsequent malignant ovarian cancer.